Shelley Chu


  • LocationSan Francisco
  • ExpertiseVenture Capital, Clinical Co-development


Gwen Kinard

Tel: + 650 926 0600

Shelley joined Abingworth in 2015 and invests across a broad range of therapeutic areas and stages of development from start-ups to late-stage to clinical co-development. She serves on the Board of Directors for Tizona Therapeutics (acquired by Gilead 2020), IFM Therapeutics LLC (IFM acquired by BMS 2017, IFM Tre acquired by Novartis 2019, IFM Due option-to-acquire by Novartis 2019), SFJ Pharmaceuticals, Venatorx, and Q32, and she co-led Abingworth’s investments in Phathom (IPO 2019, Nasdaq: PHAT). Shelley has over 20 years of operating and investment experience in the biopharmaceutical industry, including most recently Gilead where she led R&D Strategy and Business Development in Oncology, Immunotherapy and Hepatitis B. Previously Shelley invested and co-founded biotechnology companies at Frazier Healthcare Ventures. Earlier in her career she was an investment professional at Flagship Ventures and McKinsey.

Shelley holds an MD and PhD in Biochemistry and Biophysics from UCSF, and received her BA in Molecular Biology from Princeton University. She is a first author of publications in Science and other prominent journals, a Co-Chair of the Princeton Alumni School Committee and a member of the Advisory Committee for BIO’s Investor Forum.